If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Softovac Liquifibre expands the Softovac product portfolio and provides a choice for consumers who prefer time-tested Ayurvedic ingredients
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201
ABDM Microsites Mobile Application for field officers and ABDM Microsites Dashboard launched for effective on-ground implementation and monitoring
The launch of R3SET Detox Candies positions the brand at the forefront of the wellness journey
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
10+ emerging markets, Japan & ANZ transition in final phase
Subscribe To Our Newsletter & Stay Updated
